Researchers Behind COVID-19 RECOVERY Trial Launch New Monkeypox Treatment Trial

Researchers Behind COVID-19 RECOVERY Trial Launch New Monkeypox Treatment Trial
  • The U.K.-based Oxford University researchers behind the COVID-19 treatment trial RECOVERY are back again, this time for a randomized controlled trial assessing SIGA Technologies Inc's SIGA smallpox treatment Tpoxx (tecovirimat) for monkeypox.
  • The National Institute For Health and Care Research (NIHR) has commissioned and funded the study with a £3.7 million award. The first patients have now been recruited.
  • The FDA approved tecovirimat in 2018 for smallpox in adults and children. The CDC has been using an expanded access program for monkeypox.
  • Also Read: Experts Cast Doubt On Dependence On Monkeypox Vaccine Amid Limited Trial Data, Supply Crunch.
  • And although the antiviral is only approved as a smallpox treatment, its FDA approval was based on studies in nonhuman primates infected with monkeypox.
  • The trial of tecovirimat in non-hospitalized monkeypox patients will test the efficacy and safety of tecovirimat for monkeypox.
  • The trial is looking to enroll about 500 participants. The trial will test 600 mg of tecovirimat twice daily for 14 days versus a placebo.
  • Price Action: SIGA shares are down 4.80% at $21.21 on the last check Tuesday.

Posted In: BriefsMonkeypoxBiotechNewsHealth CareSmall CapGeneral